PubRank

S Z Goldhaber

Author PubWeight™ 142.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985 9.28
2 An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989 6.87
3 Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993 5.19
4 Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997 3.13
5 Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion. Radiology 1993 3.07
6 Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest 1995 2.95
7 Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992 2.63
8 Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990 2.14
9 Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest 1996 2.14
10 Clinical uses of low-molecular-weight heparins. Chest 1999 2.05
11 Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996 2.01
12 Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest 1998 1.81
13 Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995 1.78
14 Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996 1.78
15 Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014 1.74
16 Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998 1.69
17 Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest 1994 1.64
18 D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006 1.62
19 Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982 1.56
20 Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001 1.46
21 Pulmonary embolism presenting as seizures. Chest 1997 1.46
22 Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. Chest 1998 1.45
23 Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med 1995 1.44
24 Pulse-spray thrombolysis: the "careful analysis". Radiology 1994 1.42
25 Physical exercise and reduced risk of nonfatal myocardial infarction. Am J Epidemiol 1995 1.37
26 An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991 1.36
27 Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994 1.35
28 Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995 1.30
29 Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983 1.28
30 Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997 1.27
31 Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997 1.25
32 Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990 1.25
33 Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995 1.24
34 Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2009 1.22
35 Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992 1.20
36 Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982 1.15
37 A free-floating approach to filters. Arch Intern Med 1997 1.08
38 The perils of D-dimer in the medical intensive care unit. Crit Care Med 2000 1.07
39 Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986 1.06
40 Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984 1.06
41 Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol 2013 1.01
42 Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1992 1.01
43 Cancer and venous thromboembolism. Am Heart J 1996 1.01
44 Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997 1.00
45 Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol 1992 0.99
46 Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J 1994 0.98
47 Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost 2014 0.97
48 Chronic venous insufficiency: mechanisms and management. Am Heart J 1996 0.96
49 Clinically significant venous thromboembolism after gynecologic surgery. J Reprod Med 1999 0.96
50 Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine. Ann Emerg Med 1988 0.96
51 Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol 1999 0.96
52 Ovarian vein thrombosis. Am Heart J 1993 0.95
53 Biochemical markers of compliance in the Physicians' Health Study. Am J Prev Med 1991 0.95
54 The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J 1991 0.92
55 Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997 0.92
56 Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J 1991 0.91
57 Chest radiographs in acute pulmonary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest 2000 0.90
58 Cardiovascular effects of potential occupational hazards. J Am Coll Cardiol 1983 0.89
59 Fiberoptics: morbidity and cost. N Engl J Med 1973 0.89
60 Inosine: a protective agent in an organ culture model of myocardial ischemia. Circ Res 1982 0.89
61 Constrictive pericarditis: a case requiring pericardiectomy following Dressler's postmyocardial infarction syndrome. J Thorac Cardiovasc Surg 1981 0.89
62 Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost 2006 0.88
63 Time trends in hospital mortality and diagnosis of pulmonary embolism. Am Heart J 1982 0.87
64 Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987 0.86
65 Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thromb Haemost 2009 0.86
66 Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol 1996 0.86
67 Rapidly progressing dyspnea associated with a mass in the right side of the heart. Chest 1995 0.85
68 Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol 1992 0.84
69 Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992 0.84
70 Effects of the fiberoptic laparoscope and colonoscope on morbidity and cost. Ann Surg 1974 0.84
71 Thrombolysis in pulmonary embolism: a large-scale clinical trial is overdue. Circulation 2001 0.83
72 Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am Heart J 1988 0.83
73 Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995 0.83
74 Prevention by nifedipine of cold pressor-induced decrease in left ventricular ejection fraction. J Am Coll Cardiol 1983 0.83
75 Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance. Radiology 1992 0.83
76 Valvular heart disease (aortic regurgitation and mitral valve prolapse) among institutionalized adults with Down's syndrome. Am J Cardiol 1986 0.82
77 Rescue percutaneous coronary intervention immediately following coronary artery bypass grafting. Chest 2001 0.82
78 Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 1999 0.82
79 Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation 1997 0.82
80 Utility of leg ultrasonography in suspected symptomatic isolated calf deep venous thrombosis. Am J Med 1995 0.81
81 Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996 0.81
82 Contemporary use of laboratory tests to monitor safety and efficacy of thrombolytic therapy. Chest 1992 0.80
83 G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001 0.80
84 High frequency of mitral valve prolapse and aortic regurgitation among asymptomatic adults with Down's syndrome. JAMA 1987 0.80
85 Low sensitivity of plasma DNA in screening for pulmonary embolism. Am Rev Respir Dis 1982 0.80
86 Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991 0.80
87 Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 1997 0.79
88 Epidemiologic characteristics, management, and outcome of deep venous thrombosis in a tertiary-care hospital: the Brigham and Women's Hospital DVT registry. Am Heart J 1996 0.79
89 Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J 1997 0.79
90 Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Vasc Med 2001 0.79
91 Measurement of infarct size using single photon emission computed tomography and technetium-99m pyrophosphate: a description of the method and comparison with patient prognosis. Am J Cardiol 1982 0.79
92 Uses of low-molecular-weight heparin. Blood Rev 1995 0.79
93 How to select patients with deep vein thrombosis for tPA therapy. Chest 1989 0.78
94 Late venous thromboembolic disease after radical prostatectomy: effect of risk factors, warfarin and early discharge. J Urol 1997 0.78
95 Intermittent pneumatic compression in chronic venous insufficiency favorably affects fibrinolytic potential and platelet activation. Blood Coagul Fibrinolysis 1996 0.77
96 Pulmonary embolism death rates. Am Heart J 1988 0.77
97 Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. Circulation 1987 0.77
98 Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. The TIPE Investigators. Chest 1989 0.77
99 A critical pathway to evaluate suspected deep vein thrombosis. Arch Intern Med 1995 0.77
100 Frequency of pulmonary embolism in patients with low-probability lung scan and negative lower extremity venous ultrasound. Chest 1999 0.77
101 Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest 1998 0.77
102 Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med 2002 0.77
103 Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J 1984 0.76
104 The importance of rapidly treating patients with acute myocardial infarction. Chest 1995 0.76
105 Pulmonary embolic disease: diagnosis, pathophysiologic aspects, and treatment with thrombolytic therapy. Curr Probl Cardiol 1993 0.76
106 Laboratory parameters to monitor safety and efficacy during thrombolytic therapy. Chest 1991 0.76
107 Elevation of troponin I levels in patients without evidence of myocardial injury. JAMA 1998 0.76
108 Isolated calf vein thrombosis: comparison of MR venography and conventional venography after initial sonography in symptomatic patients. Acad Radiol 2001 0.76
109 Pulmonary embolism for cardiologists. J Am Coll Cardiol 1997 0.75
110 Tributes to Lewis Dexter. Tex Heart Inst J 2001 0.75
111 Pulmonary embolism thrombolysis: Do we need another agent? Am Heart J 1999 0.75
112 Conjunctive heparin therapy. Limitations of subcutaneous administration. Circulation 1992 0.75
113 Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg Am 1990 0.75
114 Thromboembolism management in Europe vs North America: are the differences clinically significant? Chest 2000 0.75
115 Bolus and accelerated thrombolysis. Experimental observations and clinical management of myocardial infarction and pulmonary embolism. Chest 1995 0.75
116 Variation in the management of deep vein thrombosis: implications for the potential impact of a critical pathway. Am J Med 1996 0.75
117 Cost benefit of intermittent pneumatic compression for venous thromboembolism prophylaxis in general surgery. Int Angiol 2008 0.75
118 Pulmonary embolism: segmental appearance of perfusion lung scan defects correlates with successful response to thrombolytic therapy. Radiology 1990 0.75
119 Imaging. Improving healthcare delivery. Lancet 1999 0.75
120 Prolonged bleeding time as a marker of venous clot lysis during streptokinase therapy. Am Heart J 1991 0.75
121 Program for the prevention of venous thromboembolism in high-risk orthopaedic patients. J Arthroplasty 1991 0.75
122 Digital subtraction pulmonary angiography--an internist's and radiologist's view. Cardiovasc Intervent Radiol 1983 0.75
123 Thrombolytic therapy for venous thromboembolism. Baillieres Clin Haematol 1990 0.75
124 Detection of pulmonary perfusion defects by single photon emission computed tomography (SPECT). J Nucl Med Allied Sci 1988 0.75
125 Urokinase versus tissue plasminogen activator in pulmonary embolism. Lancet 1988 0.75
126 Medical education: Harvard reverts to tradition. Science 1973 0.75
127 Medicine without frills: a rural hospital in Colombia. Science 1975 0.75
128 Cardiac surgery for adults with mental retardation. Dilemmas in management. Am J Med 1985 0.75
129 Spontaneous remission and prolonged survival in postinfarction cardiomyopathy. Am Heart J 1986 0.75
130 TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial. Vasa Suppl 1989 0.75
131 Deep venous thrombosis: early discharge strategies and outpatient management. J Thromb Thrombolysis 1999 0.75
132 Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy. Chest 1990 0.75
133 Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J 1996 0.75
134 Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator. Semin Thromb Hemost 1987 0.75
135 The bleeding time: its potential utility among patients receiving thrombolytic therapy. Am Heart J 1990 0.75
136 Use of enoxaparin in a patient with unstable angina. J Invasive Cardiol 2000 0.75
137 Venous thromboembolism prophylaxis in the craniotomy patient: an editorial. Surg Neurol 1998 0.75
138 Appalachia: 2 approaches in student summer health projects. Science 1970 0.75
139 The International Cooperative Pulmonary Embolism Registry. Chest 1995 0.75
140 'Beverly Hills, 90210': The lap belts don't show on TV. JAMA 1992 0.75
141 Effects of reduced coronary flow on thallium-201 accumulation and release in an in vitro rat heart preparation. Am J Cardiol 1983 0.75
142 HEW decentralizers exempt research. Science 1970 0.75
143 Student-student polarization plagues u.s. Campuses. Science 1970 0.75
144 Echocardiography in the diagnosis and management of pulmonary embolism: a limerick. Chest 2000 0.75
145 Medical school admissions: a raw deal for applicants. Science 1972 0.75
146 Fixed low-dose versus adjusted higher-dose warfarin following orthopedic surgery. A randomized prospective trial. J Arthroplasty 1994 0.75
147 Recent advances in diagnosis of pulmonary embolism and deep venous thrombosis. Am Rev Respir Dis 1988 0.75
148 CBW: interagency conflicts stall Administration action. Science 1970 0.75
149 Interruption of the inferior vena cava by clip or filter. Am J Med 1984 0.75
150 Intraoperative detection of pulmonary thromboemboli with epicardial echocardiography. Chest 1999 0.75
151 Impact of lung scanning on the management of suspected pulmonary embolism. Am Heart J 1987 0.75
152 Effects of ischemic-like insult on myocardial thallium-201 accumulation. Circulation 1983 0.75
153 Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagul Fibrinolysis 1997 0.75
154 Interruption of the inferior vena cava for prevention of pulmonary embolism: transvenous filter devices. Herz 1989 0.75
155 Anticoagulation and hemostasis in cardiac surgical patients. J Card Surg 1994 0.75
156 Administration of epinephrine by emergency medical technicians. N Engl J Med 2000 0.75
157 Cancer and venous thromboembolism. Arch Intern Med 1987 0.75
158 Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Radiology 1988 0.75
159 A critical pathway to treat proximal lower-extremity deep vein thrombosis. Am J Med 1996 0.75